Global Immune Thrombocytopenia Market Report and Forecast 2023-2031

Global Immune Thrombocytopenia Market Report and Forecast 2023-2031


Global Immune Thrombocytopenia Market Outlook:


The global immune thrombocytopenia market value was USD 3.12 billion in 2022, driven by the increasing advancements in diagnostic techniques across the globe. The market size is anticipated to grow at a CAGR of 0.9% during the forecast period of 2023-2031 to achieve a value of USD 3.39 billion by 2031.

Introduction

Immune Thrombocytopenia (ITP) is a hematologic disorder characterized by a low platelet count due to immune system dysfunction. Platelets are essential for blood clotting, and a decrease in their count can lead to increased bleeding and bruising. ITP can be classified as either primary (idiopathic) or secondary to an underlying condition or medication.

ITP is caused by the immune system mistakenly targeting and destroying platelets, leading to their reduced lifespan. The exact cause of this immune response is still not fully understood, but it is believed to involve the production of autoantibodies that bind to platelets, marking them for destruction by the spleen and other immune cells.

The symptoms of ITP can vary from mild to severe and may include easy bruising, petechiae (small red spots on the skin), nosebleeds, and excessive bleeding from cuts or injuries. In severe cases, internal bleeding and hemorrhage may occur, requiring immediate medical attention.

Key Trends in the Immune Thrombocytopenia Market


Some key trends involved in the immune thrombocytopenia market are as follows:

Advancements in Novel Therapies: There is a growing focus on the development of targeted and immunomodulatory therapies for ITP. Biologics, such as monoclonal antibodies targeting specific immune cells or receptors involved in platelet destruction, are being explored as potential treatment options. These therapies aim to improve response rates, reduce side effects, and provide long-term remission.
Personalized Medicine Approaches: With advancements in genomics and molecular diagnostics, there is an increasing emphasis on personalized medicine approaches for ITP. Genetic testing and biomarker analysis help identify patients who are more likely to respond to specific treatments, enabling more tailored and effective therapy selection
Patient-Centric Care: There is a growing recognition of the importance of patient-centered care in managing ITP. Healthcare providers are focusing on shared decision-making, considering patient preferences, and providing comprehensive support to improve treatment adherence and quality of life.
Research and Clinical Trials: Ongoing research and clinical trials are expanding the understanding of ITP pathophysiology and exploring innovative treatment modalities. These studies aim to uncover new therapeutic targets, optimize existing treatments, and identify potential biomarkers for disease monitoring and prediction.
In conclusion, Immune Thrombocytopenia is a hematologic disorder characterized by a low platelet count due to immune system dysfunction. The market for ITP therapeutics is driven by the increasing prevalence of the condition and the need for effective treatments. Advancements in novel therapies, personalized medicine approaches, patient-centric care, and ongoing research contribute to the evolving landscape of ITP management.

Immune Thrombocytopenia Market Segmentations


Market Breakup by Drug Class

Monoclonal Antibodies
Adult Vaccines
Checkpoint Inhibitors
Interferons Alpha and Beta
Interleukins
Other Drugs
Market Breakup by Applications

Cancer
Autoimmune and Inflammatory Diseases
Infectious Diseases
Others
Market Breakup by Route of Administration

Oral
Parenteral
Others
Market Breakup by End User

Hospitals
Specialty Centres
Clinics
Others
Market Breakup by Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
Market Breakup by Region

North America
United States of America
Canada
Europe
United Kingdom
Germany
France
Italy
Others
Asia Pacific
China
Japan
India
ASEAN
Australia
Others
Latin America
Brazil
Argentina
Mexico
Others
Middle East and Africa
Saudi Arabia
United Arab Emirates
Nigeria
South Africa
Others

Immune Thrombocytopenia Market Scenario


The market for Immune Thrombocytopenia (ITP) therapeutics is experiencing significant growth due to the increasing prevalence of ITP worldwide and the rising demand for effective treatment options. ITP affects individuals of all ages, with both children and adults being susceptible to the condition. The market is characterized by the presence of a wide range of treatment options, including corticosteroids, immunoglobulins, thrombopoietin receptor agonists, and splenectomy.

Several factors contribute to the growth of the ITP market. Firstly, there is a growing awareness about ITP among healthcare professionals and patients, leading to improved diagnosis rates and early intervention. Additionally, advancements in diagnostic techniques, such as platelet antibody testing and genetic profiling, are enhancing the accuracy of ITP diagnosis and enabling personalized treatment approaches

Another key driver is the increasing research and development activities in the field of ITP therapeutics. Pharmaceutical companies are investing in the development of novel therapies with improved efficacy and safety profiles. The focus is on targeted therapies that modulate the immune response and restore normal platelet production and function.

Immune Thrombocytopenia Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

Abbott
PerkinElmer Inc.
Illumina, Inc.
QIAGEN
F. Hoffmann-La Roche Ltd.
Novartis AG
AstraZeneca
Pfizer Inc.
Sanofi
Johnson & Johnson Services, Inc.
AbbVie Inc.
Allergan
Merck & Co., Inc.
Amgen Inc.
Thermo Fisher Scientific
Teva Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited.
GlaxoSmithKline plc.
Lupin Pharmaceuticals, Inc.
Lilly
Bristol-Myers Squibb Company
Boehringer Ingelheim International GmbH


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Immune Thrombocytopenia Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Immune Thrombocytopenia Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Immune Thrombocytopenia Epidemiology (2016-2031)
5.3 Europe Immune Thrombocytopenia Epidemiology (2016-2031)
5.4 Asia-Pacific Immune Thrombocytopenia Epidemiology (2016-2031)
5.5 Latin America Immune Thrombocytopenia Epidemiology (2016-2031)
5.6 Middle East & Africa Immune Thrombocytopenia Epidemiology (2016-2031)
6 Global Immune Thrombocytopenia Market Overview
6.1 Global Immune Thrombocytopenia Market Historical Value (2016-2022)
6.2 Global Immune Thrombocytopenia Market Forecast Value (2023-2031)
7 Global Immune Thrombocytopenia Market Landscape
7.1 Global Immune Thrombocytopenia: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Immune Thrombocytopenia Product Landscape
7.2.1 Analysis by Treatment Type
7.2.2 Analysis by Route of Administration
7.2.3 Analysis by End User
8 Immune Thrombocytopenia Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Immune Thrombocytopenia Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Immune Thrombocytopenia Market Segmentation
11.1 Global Immune Thrombocytopenia Market by Treatment Type
11.1.1 Market Overview
11.1.2 Medications
11.1.2.1 Thrombopoietin Receptor Agonists
11.1.2.2 Corticosteroids
11.1.2.3 Intravenous Immunoglobulins
11.1.2.4 Others
11.1.3 Surgery
11.2 Global Immune Thrombocytopenia Market by Diseases Type
11.2.1 Market Overview
11.2.2 Acute
11.2.3 Chronic
11.3 Global Immune Thrombocytopenia Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Injectable
11.4 Global Immune Thrombocytopenia Market by End User
11.4.1 Market Overview
11.4.2 Hospitals
11.4.3 Homecare
11.4.4 Specialty Centres
11.4.5 Others
11.5 Global Immune Thrombocytopenia Market by Treatment Channel
11.5.1 Market Overview
11.5.2 Public
11.5.3 Private
11.6 Global Immune Thrombocytopenia Market by Distribution Channel
11.6.1 Market Overview
11.6.2 Hospital Pharmacy
11.6.3 Online Pharmacy
11.6.4 Retail Pharmacy
11.7 Global Immune Thrombocytopenia Market by Region
11.7.1 Market Overview
11.7.2 North America
11.7.3 Europe
11.7.4 Asia Pacific
11.7.5 Latin America
11.7.6 Middle East and Africa
12 North America Immune Thrombocytopenia Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Immune Thrombocytopenia Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Immune Thrombocytopenia Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Immune Thrombocytopenia Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Immune Thrombocytopenia Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Pfizer Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 F. Hoffmann-La Roche Ltd.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Mylan N.V.
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Fresenius Kabi AG
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Hikma Pharmaceuticals PLC
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Hepalink Group.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Teva Pharmaceutical Industries Ltd.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Amarillo Biosciences, Inc.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Bolder Bio Technology, Inc.
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 GENOSCO Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Hansa Biopharma
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Janssen Pharmaceuticals, Inc.
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 Eisai Co., Ltd (Japan)
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
24 Immune Thrombocytopenia Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings